O’Neil, B. H., Bernard, S. A., Goldberg, R. M., Moore, D. T., Garcia, R., Marroquin, C., … Sanoff, H. K. (2008). Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma. Journal of Clinical Oncology, 26(15_suppl), 4604–4604. https://doi.org/10.1200/jco.2008.26.15_suppl.4604

O’Neil, B. H., S. A. Bernard, R. M. Goldberg, D. T. Moore, R. Garcia, C. Marroquin, M. A. Morse, L. Woods, and H. K. Sanoff. “Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 4604–4604. https://doi.org/10.1200/jco.2008.26.15_suppl.4604.

O’Neil BH, Bernard SA, Goldberg RM, Moore DT, Garcia R, Marroquin C, et al. Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma. Journal of Clinical Oncology. 2008 May 20;26(15_suppl):4604–4604.

O’Neil, B. H., et al. “Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma.” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2008, pp. 4604–4604. Crossref, doi:10.1200/jco.2008.26.15_suppl.4604.

O’Neil BH, Bernard SA, Goldberg RM, Moore DT, Garcia R, Marroquin C, Morse MA, Woods L, Sanoff HK. Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008 May 20;26(15_suppl):4604–4604.